肺癌并發靜脈血栓栓塞癥的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

潘穎超 ,  陸月明

解放軍第455醫院呼吸內科（上海 200052）;

Corresponding?author：

陸月明, Email: drlu06@126.com

Keywords：

DOI：

10.7507/1671-6205.2016143

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 潘穎超, 陸月明. 肺癌并發靜脈血栓栓塞癥的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2016, 15(6): 624-627. doi: 10.7507/1671-6205.2016143 Copy

1.	Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer:a systematic review and meta-analysis. PLoS Med, 2012, 9:e1001275.
2.	Steuer CE, Behera M, Kim S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients:a nationwide inpatient sample database analysis. Lung Cancer, 2015, 88:80-84.
3.	Ay C, Vnal UK. Epidemiology and risk factors for venous thromboembolism in lung cancer. Curr Opin Oncol, 2016, 28:145-149.
4.	Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer:a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer, 2009, 115:5516-5525.
5.	Zhang Y, Yang Y, Chen W, et al. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest, 2014, 146:650-658.
6.	Lee JE, Kim HR, Lee SM, et al. Clinical characteristics of pulmonary embolism with underlying malignancy. Korean J Intern Med, 2010, 25:66-70.
7.	van Herk-Sukel MP, Shantakumar S, Penning-van Beest FJ, et al. Pulmonary embolism, myocardial infarction, and ischemic stroke in lung cancer patients:results from a longitudinal study. Lung, 2013, 191:501-509.
8.	Lee YG, Kim I, Lee E, et al. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost, 2014, 111:1112-1120.
9.	許小毛, 楊鶴, 喬立松, 等.肺癌合并靜脈血栓栓塞癥患者的臨床特點及預后分析.中華醫學雜志, 2014, 94:2045-2049.
10.	Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost, 2008, 6:601-608.
11.	Zhang Y, Yang Y, Chen W, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep, 2016, 6:19603.
12.	Connolly GC, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism among ambulatory patients with lung cancer. Lung Cancer, 2012, 78:253-258.
13.	Wang Z, Yan HH, Yang JJ, et al. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer, 2015, 23:635-641.
14.	Yang Y, Zhou Z, Niu XM, et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol, 2012, 106:736-741.
15.	Huang H, Korn JR, Mallick R, et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality:a retrospective database study. J Thromb Thrombolysis, 2012, 34:446-456.
16.	Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis:result of a retrospective analysis of the PROTECHT study. J Transl Med, 2011, 9:179.
17.	Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery:extending the case for extended prophylaxis. Ann Surg, 2011, 254:131-137.
18.	Dutta TK, Venugopal V. Venous thromboembolism:the intricacies. J Postgrad Med, 2009, 55:55-64.
19.	Rodrigues CA, Ferrarotto R, Kalil Filho R, et al. Venous thromboembolism and cancer:a systematic review. J Thromb Thrombolysis, 2010, 30:67-78.
20.	Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol, 2009, 27:4834-4838.
21.	Han X, Guo B, Li Y, et al. Tissue factor in tumor microenvironment:a systematic review. J Hematol Oncol, 2014, 7:54.
22.	Langer F. Haemostatic aspects in clinical oncology. Hamostaseologie, 2015, 35:152-164.
23.	Versteeg HH, Spek CA, Peppelenbosch MP, et al. Tissue factor and cancer metastasis:the role of intracellular and extracellular signaling pathways. Mol Med, 2004, 10:6-11.
24.	Nomura S, Niki M, Nisizawa T, et al. Microparticles as biomarkers of blood coagulation in cancer. Biomark Cancer, 2015, 7:51-56.
25.	Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer, 2012, 13:482-487.
26.	Mavromatis BH, Kessler CM. D-dimer testing:the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol, 2001, 54:664-668.
27.	Go SI, Lee A, Lee US, et al. Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer. Lung Cancer, 2014, 84:79-85.
28.	Go SI, Kim RB, Song HN, et al. Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism. Tumour Biol, 2015, 36:7631-7639.
29.	Corrales-Rodriguez L, Soulières D, Weng X, et al. Mutations in NSCLC and their link with lung cancer-associated thrombosis:a case-control study. Thromb Res, 2014, 133:48-51.
30.	Wang J, Guan W, Chen D, et al. The value of CTPA for diagnosing acute pulmonary thromboembolism and the ensuing right ventricular dysfunction. Cell Biochem Biophys, 2014, 69:517-522.
31.	Moores L, Kline J, Portillo AK, et al. Multidetector computed tomographic pulmonary angiography in patients with a high clinical probability of pulmonary embolism. J Thromb Haemost, 2016, 14:114-120.
32.	Hayes SA, Soff GA, Zabor EC, et al. Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. Clin Imaging, 2014, 38:637-640.
33.	Murthy C, Davis R, Koegelenberg CF, et al. The impact of an electronic clinical decision support for pulmonary embolism imaging on the efficiency of computed tomography pulmonary angiography utilisation in a resource-limited setting. S Afr Med J, 2015, 106:62-64.
34.	中國臨床腫瘤學會腫瘤與血栓專家共識委員會.中國腫瘤相關靜脈血栓栓塞癥預防與治療專家指南.中國實用內科雜志, 2015, 35:907-920.
35.	Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol, 2015, 33:654-656.
36.	Goodman LR, Stein PD, Matta F, et al. CT venography and compression sonography are diagnostically equivalent:data from PIOPED Ⅱ. AJR Am J Roentgenol, 2007, 189:1071-1076.
37.	Kourelis TV, Wysokinska EM, Wang Y, et al. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer, 2014, 86:358-362.
38.	Christensen TD, Vad H, Pedersen S, et al. Venous thromboembolism in patients undergoing operations for lung cancer:a systematic review. Ann Thorac Surg, 2014, 97:394-400.
39.	Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008, 111:4902-4907.
40.	Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon, 2005, 51:70-78.
41.	Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg, 2016, 151:37-44.
42.	Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage Ⅲ/Ⅳ lung cancer. Clin Appl Thromb Hemost, 2012, 18:159-165.
43.	Coleman R, MacCallum P. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer, 2010, 102(Suppl 1):S17-S23.
44.	Zhang J, Zhang YL, Ma KX, et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis. Thorax, 2013, 68:442-450.
45.	Akl EA, Muti P, Schünemann HJ. Anticoagulation in patients with cancer:an overview of reviews. Pol Arch Med Wewn, 2008, 118:183-193.
46.	Macbeth F, Noble S, Evans J, et al. Randomized phase Ⅲ trial of standard therapy plus low molecular weight heparin in patients with lung cancer:FRAGMATIC Trial. J Clin Oncol, 2016, 34:488-494.
47.	Delate T, Witt DM, Ritzwoller D, et al. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist, 2012, 17:419-427.
48.	Bobek V, Boubelik M, Fiserova A, et al. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer, 2005, 47:215-223.
49.	Zhong GX, Gong Y, Yu CJ, et al. Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism. Tumour Biol, 2015, 36:4689-4697.
50.	Altinbas M, Dikilitas M, Ozkan M, et al. The effect of small-molecular-weight heparin added to chemotherapy on survival in small-celllung cancer:a retrospective analysis. Indian J Cancer, 2014, 51:324-329.

1. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer:a systematic review and meta-analysis. PLoS Med, 2012, 9:e1001275.
2. Steuer CE, Behera M, Kim S, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients:a nationwide inpatient sample database analysis. Lung Cancer, 2015, 88:80-84.
3. Ay C, Vnal UK. Epidemiology and risk factors for venous thromboembolism in lung cancer. Curr Opin Oncol, 2016, 28:145-149.
4. Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer:a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer, 2009, 115:5516-5525.
5. Zhang Y, Yang Y, Chen W, et al. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest, 2014, 146:650-658.
6. Lee JE, Kim HR, Lee SM, et al. Clinical characteristics of pulmonary embolism with underlying malignancy. Korean J Intern Med, 2010, 25:66-70.
7. van Herk-Sukel MP, Shantakumar S, Penning-van Beest FJ, et al. Pulmonary embolism, myocardial infarction, and ischemic stroke in lung cancer patients:results from a longitudinal study. Lung, 2013, 191:501-509.
8. Lee YG, Kim I, Lee E, et al. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost, 2014, 111:1112-1120.
9. 許小毛, 楊鶴, 喬立松, 等.肺癌合并靜脈血栓栓塞癥患者的臨床特點及預后分析.中華醫學雜志, 2014, 94:2045-2049.
10. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost, 2008, 6:601-608.
11. Zhang Y, Yang Y, Chen W, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep, 2016, 6:19603.
12. Connolly GC, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism among ambulatory patients with lung cancer. Lung Cancer, 2012, 78:253-258.
13. Wang Z, Yan HH, Yang JJ, et al. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer, 2015, 23:635-641.
14. Yang Y, Zhou Z, Niu XM, et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol, 2012, 106:736-741.
15. Huang H, Korn JR, Mallick R, et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality:a retrospective database study. J Thromb Thrombolysis, 2012, 34:446-456.
16. Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis:result of a retrospective analysis of the PROTECHT study. J Transl Med, 2011, 9:179.
17. Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery:extending the case for extended prophylaxis. Ann Surg, 2011, 254:131-137.
18. Dutta TK, Venugopal V. Venous thromboembolism:the intricacies. J Postgrad Med, 2009, 55:55-64.
19. Rodrigues CA, Ferrarotto R, Kalil Filho R, et al. Venous thromboembolism and cancer:a systematic review. J Thromb Thrombolysis, 2010, 30:67-78.
20. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol, 2009, 27:4834-4838.
21. Han X, Guo B, Li Y, et al. Tissue factor in tumor microenvironment:a systematic review. J Hematol Oncol, 2014, 7:54.
22. Langer F. Haemostatic aspects in clinical oncology. Hamostaseologie, 2015, 35:152-164.
23. Versteeg HH, Spek CA, Peppelenbosch MP, et al. Tissue factor and cancer metastasis:the role of intracellular and extracellular signaling pathways. Mol Med, 2004, 10:6-11.
24. Nomura S, Niki M, Nisizawa T, et al. Microparticles as biomarkers of blood coagulation in cancer. Biomark Cancer, 2015, 7:51-56.
25. Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer, 2012, 13:482-487.
26. Mavromatis BH, Kessler CM. D-dimer testing:the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol, 2001, 54:664-668.
27. Go SI, Lee A, Lee US, et al. Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer. Lung Cancer, 2014, 84:79-85.
28. Go SI, Kim RB, Song HN, et al. Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism. Tumour Biol, 2015, 36:7631-7639.
29. Corrales-Rodriguez L, Soulières D, Weng X, et al. Mutations in NSCLC and their link with lung cancer-associated thrombosis:a case-control study. Thromb Res, 2014, 133:48-51.
30. Wang J, Guan W, Chen D, et al. The value of CTPA for diagnosing acute pulmonary thromboembolism and the ensuing right ventricular dysfunction. Cell Biochem Biophys, 2014, 69:517-522.
31. Moores L, Kline J, Portillo AK, et al. Multidetector computed tomographic pulmonary angiography in patients with a high clinical probability of pulmonary embolism. J Thromb Haemost, 2016, 14:114-120.
32. Hayes SA, Soff GA, Zabor EC, et al. Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients. Clin Imaging, 2014, 38:637-640.
33. Murthy C, Davis R, Koegelenberg CF, et al. The impact of an electronic clinical decision support for pulmonary embolism imaging on the efficiency of computed tomography pulmonary angiography utilisation in a resource-limited setting. S Afr Med J, 2015, 106:62-64.
34. 中國臨床腫瘤學會腫瘤與血栓專家共識委員會.中國腫瘤相關靜脈血栓栓塞癥預防與治療專家指南.中國實用內科雜志, 2015, 35:907-920.
35. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol, 2015, 33:654-656.
36. Goodman LR, Stein PD, Matta F, et al. CT venography and compression sonography are diagnostically equivalent:data from PIOPED Ⅱ. AJR Am J Roentgenol, 2007, 189:1071-1076.
37. Kourelis TV, Wysokinska EM, Wang Y, et al. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer, 2014, 86:358-362.
38. Christensen TD, Vad H, Pedersen S, et al. Venous thromboembolism in patients undergoing operations for lung cancer:a systematic review. Ann Thorac Surg, 2014, 97:394-400.
39. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008, 111:4902-4907.
40. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon, 2005, 51:70-78.
41. Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg, 2016, 151:37-44.
42. Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage Ⅲ/Ⅳ lung cancer. Clin Appl Thromb Hemost, 2012, 18:159-165.
43. Coleman R, MacCallum P. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer, 2010, 102(Suppl 1):S17-S23.
44. Zhang J, Zhang YL, Ma KX, et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis. Thorax, 2013, 68:442-450.
45. Akl EA, Muti P, Schünemann HJ. Anticoagulation in patients with cancer:an overview of reviews. Pol Arch Med Wewn, 2008, 118:183-193.
46. Macbeth F, Noble S, Evans J, et al. Randomized phase Ⅲ trial of standard therapy plus low molecular weight heparin in patients with lung cancer:FRAGMATIC Trial. J Clin Oncol, 2016, 34:488-494.
47. Delate T, Witt DM, Ritzwoller D, et al. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist, 2012, 17:419-427.
48. Bobek V, Boubelik M, Fiserova A, et al. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer, 2005, 47:215-223.
49. Zhong GX, Gong Y, Yu CJ, et al. Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism. Tumour Biol, 2015, 36:4689-4697.
50. Altinbas M, Dikilitas M, Ozkan M, et al. The effect of small-molecular-weight heparin added to chemotherapy on survival in small-celllung cancer:a retrospective analysis. Indian J Cancer, 2014, 51:324-329.

Previous Article
系統性糖皮質激素在呼吸危重癥治療中的獲益與風險
Next Article
Parkin依賴的線粒體自噬在慢性阻塞性肺疾病中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

肺癌并發靜脈血栓栓塞癥的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content